In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Digital Pathology Test Predicts NSCLC Patients' Response to AstraZeneca, Daiichi Sankyo's Dato-DXd
Premium
A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
Premium
Memorial Sloan Kettering Cancer Center is among the first healthcare systems to implement the rapid sequencing assay, which can consolidate single-gene tests.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.